News Aktuell

Grünenthal Group

16.11.2023 - 16:30

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a ...To the press release of Grünenthal Group

16.11.2023 - 16:30

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

02.08.2023 - 08:55

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as ...To the press release of Grünenthal Group

27.06.2023 - 10:27

Empowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced

Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people ...To the press release of Grünenthal Group

22.05.2023 - 10:14

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of ...To the press release of Grünenthal Group

27.04.2023 - 08:00

Grünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research

Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - ...To the press release of Grünenthal Group

01.03.2023 - 11:06

Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal

Aachen (ots) - Janneke van der Kamp has today assumed her role as the new Chief Commercial Officer (CCO) of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation. As CCO of ...To the press release of Grünenthal Group

One image:
Preview HiResDownload

22.11.2022 - 10:43

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer

AACHEN, Germany (ots) - Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently ...To the press release of Grünenthal Group

One image:
Preview HiResDownload

02.11.2022 - 10:35

Grünenthal closes deal to acquire testosterone therapy NebidoTM from Bayer for €495 million

Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency affects one in six men over 50 years1; representing a significant burden," said ...To the press release of Grünenthal Group

18.08.2022 - 11:48

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain

Aachen, Germany (ots) - - Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine. - The programme will be conducted across approx. 200 study sites and include ...To the press release of Grünenthal Group

04.08.2022 - 09:00

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Aachen (ots) - Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset ...To the press release of Grünenthal Group

14.07.2022 - 08:02

Grünenthal acquires testosterone treatment NebidoTM from Bayer

Aachen, Germany (ots) - - Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. - NebidoTM is the gold standard for the treatment ofmale ...To the press release of Grünenthal Group

07.07.2022 - 09:05

Grünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research

Aachen (ots) - Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of ...To the press release of Grünenthal Group